Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06237153 · ClinicalTrials.gov registry record · Phase 2
Randomized Placebo Controlled Study of Triamcinolone Acetonide Extended Release Injection for Thumb (CMC) Osteoarthritis
A Phase 2 study of Carpometacarpal (CMC) Osteoarthritis, sponsored by Marie Badalamente.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06237153: Recruiting Phase 2 study of Carpometacarpal (CMC) Osteoarthritis, sponsored by Marie Badalamente.
NCT06237153 is a Phase 2 study of Carpometacarpal (CMC) Osteoarthritis that is actively recruiting participants, run by Marie Badalamente. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06237153, a Phase 2 study of Carpometacarpal (CMC) Osteoarthritis, is actively recruiting participants, sponsored by Marie Badalamente.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to investigate if a timed release steroid injection may be beneficial in treating carpometacarpal (CMC) joint (thumb) osteoarthritis. The main questions to be answered are: 1. does the steroid injection substantially reduce pain in the thumb 2. does the steroid injection help to increase thumb function Participants will be asked to undergo a thumb CMC joint injection and to attend follow up visits to assess pain and thumb function.
Primary Outcome
PAIN
Conditions Studied
Interventions
- DRUG Triamcinolone Acetonide extended release suspension
Study Locations (1)
New York
- Stony Brook Orthopaedics - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-11-21 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
What NCT06237153 shows while recruiting
NCT06237153 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Carpometacarpal (CMC) Osteoarthritis appearing as the primary indexed condition, and to 1 intervention - of which Triamcinolone Acetonide extended release suspension is the first listed.
NCT06237153 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06237153 about?
NCT06237153 is a clinical study titled "Randomized Placebo Controlled Study of Triamcinolone Acetonide Extended Release Injection for Thumb (CMC) Osteoarthritis". The goal of this study is to investigate if a timed release steroid injection may be beneficial in treating carpometacarpal (CMC) joint (thumb) osteoarthritis. The main questions to be answered are: 1. does the steroid injection substantially reduce pain in the thumb 2. does the steroid injection h...
What is the current status of trial NCT06237153?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-11-21. Estimated completion is 2025-12-31.
What conditions does trial NCT06237153 study?
This clinical trial studies the following conditions: Carpometacarpal (CMC) Osteoarthritis.
What interventions are being tested in trial NCT06237153?
The interventions under investigation include: Triamcinolone Acetonide extended release suspension (DRUG).
Who is sponsoring clinical trial NCT06237153?
This trial is sponsored by Marie Badalamente, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06237153 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06237153's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI